Wockhardt announces exit from generic drugs business in US
Pharma company Wockhardt stated in a regulatory filing on Friday that it will exit from the US generic drugs market.
Pharma company Wockhardt stated in a regulatory filing on Friday that it will exit from the US generic drugs market.
Under the terms of the definitive agreement, Jemincare will be responsible for exclusive development and commercialisation of the Nafithromycin
